Peptide Antibiotics Market Size, Share, By Product Type (Ribosomal Synthesized Peptide Antibiotics, and Non-Ribosomal Synthesized Peptide Antibiotics), Disease (Skin Infection, HABP/VABP, Blood Stream Infection, and Others), Route of Administration (Injectable, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI589625 | Publish Date: June 2025 | No. of Pages: 165

Peptide Antibiotics Market Companies

Peptide antibiotic companies are focusing on innovation through strong R&D, strategic alliances, and cost-effective production to increase product quality and scalability. Expanding into emerging markets and utilizing state-of-the-art drug delivery techniques help to increase market reach, even though widespread adoption and long-term growth are made possible by efficient regulatory clearances and healthcare provider education. VERRA, Melinta Therapeutics LLC, AbbVie Inc., Monarch Pharmachem, Merck & Co., Inc., and others are the major companies in the peptide antibiotics market.

List of Key Players in the Market:

  • Merck & Co., Inc.
  • Monarch Pharmachem
  • BACHEM HOLDING AG
  •  Bruker Corporation
  • Melinta Therapeutics LLC
  • Pfizer Inc.
  • AbbVie Inc.
  •  GSK plc
  • Sanofi
  • Novartis AG
  • Nabriva Therapeutics plc
  • Goodness Gracious
  • Canidae Pet Foods

Recent News:

  • According to Revance Therapeutics, DAXXIFYTM (DaxibotulinumtoxinA-lanm) has received FDA approval for injection, on September 2022. As the first and only peptide-formulated neuromodulator providing long-lasting cosmetic results, this is a significant milestone for DAXXIFY. Compared to current botulinum toxin treatments, the product may have a longer duration of action and is intended to lessen the appearance of frown lines.